Table of Content

Open Access iconOpen Access

ARTICLE

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway

Wenliang Tan*†1, Sicong Zhu*†1, Jun Cao*†, Lei Zhang*†, Wenda Li*†, Kairui Liu*†, Jinyi Zhong, Changzhen Shang*†, Yajin Chen*†

* Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P.R. China
† Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P.R. China
1 These authors provided equal contribution to this work.

Oncology Research 2017, 25(9), 1543-1553. https://doi.org/10.3727/096504017X14886444100783

Abstract

Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited migration ability than with sorafenib treatment alone in both HCC cells with high and low expression of MMP-2. In vivo cell metastasis experiments confirmed the synergistic effects of sorafenib and SB-3CT in reducing lung metastasis of SK-HEP-1 cells. Mechanistically, we showed that the synergistic antitumor effect may be attributed to inhibition of the PI3K/AKT/mTOR signaling pathway, but not the RAF/MEK/ERK signaling pathway. With these results taken together, the current study demonstrates that inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2 expression, which may provide a novel strategy to improve therapeutic efficiency in HCC.

Keywords


Cite This Article

APA Style
Tan, W., Zhu, S., Cao, J., Zhang, L., Li, W. et al. (2017). Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the pi3k/akt/mtor pathway. Oncology Research, 25(9), 1543-1553. https://doi.org/10.3727/096504017X14886444100783
Vancouver Style
Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, et al. Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the pi3k/akt/mtor pathway. Oncol Res. 2017;25(9):1543-1553 https://doi.org/10.3727/096504017X14886444100783
IEEE Style
W. Tan et al., "Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway," Oncol. Res., vol. 25, no. 9, pp. 1543-1553. 2017. https://doi.org/10.3727/096504017X14886444100783



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 25

    View

  • 24

    Download

  • 0

    Like

Share Link